Connetics' Extina hits new endpoint in Phase III

Working to overcome a 2004 FDA rejection, researchers at Connetics say that Extina--an experimental therapy for seborrheic dermatitis--proved effective in a new Phase III trial. Regulators had rejected the therapy two years ago after a pivotal trial failed to show its superiority to a placebo. After the latest four-week trial involving 1,162 patients, though, 56 percent of volunteers reported an improvement in symptoms compared to 42 percent who received a placebo.

- read the report on Extina from the StreetInsider